PRKAA1 and breast carcinoma: This result was more apparent in luminal phenotype disease with further in-vitro characterisations showing that metformin, the activator of AMPK, induced ROS production in luminal breast cancer cells possibly through altered Trx system expression; with little effect in basal phenotype cells.